Apeiron Investment Group Ltd. - 01 Jul 2024 Form 4 Insider Report for BIONOMICS LTD/ADR

Role
10%+ Owner
Signature
Apeiron Investment Group Ltd. By: /s/ Mario Frendo, Director
Issuer symbol
N/A
Transactions as of
01 Jul 2024
Net transactions value
-$82,527
Form type
4
Filing time
07 Oct 2024, 18:22:49 UTC
Previous filing
17 Apr 2024
Next filing
19 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BNOX Ordinary Shares Sale $29,966 -90,806 -0.07% $0.3300 125,996,580 02 Oct 2024 By Apeiron Presight Capital Fund II, L.P. F1, F2
transaction BNOX Ordinary Shares Sale $52,405 -180,707 -0.19% $0.2900 93,469,320 03 Oct 2024 By Apeiron Presight Capital Fund II, L.P. F1, F2
transaction BNOX Ordinary Shares Sale $156 -557 -0% $0.2800 93,369,060 04 Oct 2024 By Apeiron Presight Capital Fund II, L.P. F1, F2
holding BNOX Ordinary Shares 183,121,441 01 Jul 2024 By Apeiron Investment Group Ltd. F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Apeiron Investment Group Ltd. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Includes Ordinary Shares represented by American Depositary Shares.
F2 The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities.
F3 The reportable securities are held by Apeiron. Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities.